Macular Degeneration Trial, Recruiting NCT05932069 Sponsor: VA Office of Research and Development Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT05932069
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a Veteran who has been diagnosed with an intermediate stage of age-related macular degeneration (AMD) in at least one eye
  • You are between 65 and 89 years old
  • You are willing and able to take part in the study's activities and assessments
  • You have scored above 26 on a standard memory and thinking test, meaning your thinking and memory are considered to be in the normal range
  • You do not have any serious conditions that affect your thinking or your ability to do light aerobic exercise (such as serious heart, liver, or kidney disease)
  • You do not have any conditions or injuries that directly affect how your brain works (such as a serious head injury, stroke, epilepsy, or a progressive brain disease)
  • You have reliable internet access at home
  • English is your first language and you have completed high school

Who may not be able to join:

  • You have vision problems in your eyes that are caused by something other than AMD
  • You have a history of a major mental health condition, such as psychosis, severe depression, or bipolar disorder
  • You currently have an alcohol or substance use disorder
  • You have heart disease or have previously had a heart attack

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joe R. Nocera, PhD, Atlanta VA Medical and Rehab Center, Decatur, GA

Phone: (404) 321-6111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
31 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

contrast sensitivity; Dark adaptometry

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov